Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADX-038 in Complement-Mediated Kidney Disease
NCT06989359Phase 2Recruiting
- Sponsor
- ADARx Pharmaceuticals
- Start
- Aug 2025
- Primary completion
- Dec 2028
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 8
01
Overview
A Phase 2 trial of agazisiran in IgA nephropathy (IgAN), Complement 3 glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), sponsored by ADARx Pharmaceuticals. Started Aug 2025; status: recruiting.
02
Drugs
agazisiran
03
Conditions
IgA nephropathy (IgAN)Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on NCT06989359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06989359.